T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen‐activated protein kinase mechanism
Open Access
- 3 April 2003
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (4) , 993-1001
- https://doi.org/10.1002/art.10872
Abstract
Objective: To investigate the role of T cell induction of matrix metalloproteinase 13 (MMP‐13) production by human osteoblasts in order to better understand the process of bone loss in rheumatoid arthritis (RA).Methods: Activated T cell–conditioned medium (ACTTCM) was used to mimic the physiologic conditions of inflammation. MMP‐13 production by human osteoblasts was assessed using a specific enzyme‐linked immunosorbent assay. Specific inhibitors of the p38 mitogen‐activated protein (MAP) kinase and the extracellular signal–regulated kinase 1/2 (ERK‐1/2) MAP kinase signaling pathways were used to assess their roles in T cell–mediated MMP‐13 production. Finally, recombinant cytokines representative of the major components in ACTTCM were assessed for their ability to induce MMP‐13.Results: ACTTCM powerfully induced MMP‐13 in human osteoblasts. Inhibition of p38 activity abolished, while inhibition of ERK‐1/2 activity enhanced, MMP‐13 production. We next investigated physiologic levels of the T cell cytokines tumor necrosis factor α (TNFα), transforming growth factor β (TGFβ), interferon‐γ (IFNγ), and interleukin‐17 (IL‐17) for their roles in MMP‐13 induction. Although individual cytokines had no significant effect, the combination of TNFα, TGFβ, IFNγ, and IL‐17 resulted in a dramatic p38‐dependent induction of MMP‐13 identical to that produced by ACTTCM.Conclusion: These studies demonstrate for the first time that human osteoblasts produce MMP‐13. The results also show that under conditions of chronic inflammation, multiple T cell cytokines synergize to induce high levels of MMP‐13 via a mechanism that is dependent on activated p38 MAP kinase and is suppressed by activated ERK‐1/2. Selective inhibition of p38 activity may offer a target for pharmacologic inhibition of bone loss in RA.Keywords
This publication has 51 references indexed in Scilit:
- Physical Interaction of the Activator Protein-1 Factors c-Fos and c-Jun with Cbfa1 for Collagenase-3 Promoter ActivationJournal of Biological Chemistry, 2002
- The combination of tumor necrosis factor ? blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo modelArthritis & Rheumatism, 2001
- Basic Fibroblast Growth Factor Stimulates Vascular Endothelial Growth Factor Release in Osteoblasts: Divergent Regulation by p42/p44 Mitogen-Activated Protein Kinase and p38 Mitogen-Activated Protein KinaseJournal of Bone and Mineral Research, 2000
- Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cellsJournal of Cellular Physiology, 2000
- Pathogenesis of bone erosions in rheumatoid arthritisCurrent Opinion in Rheumatology, 2000
- Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun N-terminal kinase, and nuclear factor κB: Differential regulation of collagenase 1 and collagenase 3Arthritis & Rheumatism, 2000
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJournal of Clinical Investigation, 1999
- The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis.Journal of Clinical Investigation, 1996
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- BONE MASS MEASUREMENT AND BONE METABOLISM IN RHEUMATOID ARTHRITIS: A REVIEWRheumatology, 1996